Miraculins Announces 2014 Plans for its Scout DS Non-Invasive Diabetes Screening Technology

November 21, 2013

Miraculins Inc. (TSX-V:MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce its plans for the Scout DS®non-invasive diabetes screening technology for the upcoming fiscal year, which will include U.S. regulatory activity and expected sales expansion within Canadian pharmacy and employee health screening markets.

The Scout DS is the world's first non-invasive and highly-sensitive screening test for pre-diabetes and type 2 diabetes. It does not require a blood draw or fasting and generates a result in as little as 80 seconds. The Scout DS uses visible light to measure the optical signature of markers in the skin that accumulate due to damage caused by abnormal blood sugar levels and oxidative stress.

"Our team has been diligently advancing the Scout DS since our acquisition of this exciting technology approximately 90 days ago," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "Our 2014 plans for the Scout DS will see our team engaged in key initiatives for driving product growth and adoption."

In the short period since the acquisition of the Scout DS technology closed, the Company has significantly advanced various initiatives to maintain and build Scout DS market momentum, including:

Maintaining ISO:13485 and ISO:9001 certification of the Scout DS manufacturing facility in New Mexico, by successfully passing an ISO audit;
Enabling new scientific research studies, with third party collaboration, exploring the potential for new market segments and test utility expansion;
Re-appointing Pear Healthcare Solutions as the distributor of the Scout DS® to the Canadian Pharmacy segment;
Facilitating placement of the Scout DS into a major Canadian retail/food pharmacy chain pilot program;
Entering into a Letter of Intent to negotiate the licensing rights for the Scout DS in China;
Evaluating previous international Scout DS distributors to identify opportunities for re-appointment; and
Developing a regulatory strategy for the preparation of a submission to the FDA to gain approval for sale and distribution of the Scout DS in the United States.
 

Click here for the full story.

Share This Story

Back

"Our team has been diligently advancing the Scout DS since our acquisition of this exciting technology approximately 90 days ago," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc.